UroGen Pharma Ltd. URGN
28.74 USD -5.66 (-16.45%)
At closeNov 4, 2026, 4:00 PM EST
28.74 0.00 0.00%
After hours · Nov 4, 4:00 PM ET
27.55 Day range 34.17
16.50 52-week range 50.81
- YTD
- +22.72%
- 1 year
- +45.08%
News
marketbeat.com Urogen Pharma Q3 Earnings Call Highlights Urogen Pharma NASDAQ: URGN reported third-quarter revenue of $89 million, more than triple the $27.5 million recorded a year earlier, as sales of bladder cancer treatment ZUSDURI continued to grow.…
fool.com The Gel That Became a Business Zosturi quarterly net product revenue reached $68 million. Repeat prescribers expanded to 50% of total Zosturi writers.
seekingalpha.com UroGen Pharma Ltd. (URGN) Q3 2026 Earnings Call Transcript UroGen Pharma Ltd. ( URGN ) Q3 2026 Earnings Call November 4, 2026 10:00 AM EST Company Participants Vincent Perrone - Senior Director of Investor Relations Elizabeth Barrett - President, CEO &…
benzinga.com UroGen Pharma Q3 2026 Earnings Call Transcript UroGen Pharma (NASDAQ:URGN) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
zacks.com Urogen Pharma (URGN) Reports Q3 Loss, Beats Revenue Estimates Urogen Pharma (URGN) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of $0.05. This compares to a loss of $0.69 per share a year ago.
benzinga.com UroGen Pharma Q3 EPS $(0.03) Misses $0.14 Estimate, Sales $89.001M Miss $89.918M Estimate UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $0.14 by 121.43 percent. This is a 95.65 percent increase over losses of…
globenewswire.com UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights ZUSDURI ® generated $68.0 million in revenue in the third quarter of 2026, representing 35% quarter-over-quarter growth The FDA accepted UroGen's NDA for UGN-103 (next-generation novel…
globenewswire.com UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference PRINCETON, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
globenewswire.com UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer Phase 1 clinical trial to evaluate local intravesical administration of UGN-501 UGN-501 is a differentiated investigational next-generation oncolytic virus designed to combine direct tumor cell…
benzinga.com UroGen Pharma Shares Results From 5-Year Follow-Up Study On Olympus Five-year Olympus follow-up data published in Therapeutic Advances in Urology reinforce the long-term durability of response with JELMYTOResults demonstrate sustained disease control through extended…
globenewswire.com UroGen's Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer Five-year Olympus follow-up data published in Therapeutic Advances in Urology reinforce the long-term durability of response with JELMYTO Results demonstrate sustained disease control through…
globenewswire.com UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026 Conference Call and Webcast Scheduled for Wednesday, November 4th, 2026, at 10:00 AM ET Conference Call and Webcast Scheduled for Wednesday, November 4th, 2026, at 10:00 AM ET
benzinga.com HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $75 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $75 price target.
globenewswire.com UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and…
seekingalpha.com UroGen Pharma: An Emerging GARP Stock UroGen Pharma has pulled back 30% after a 208% rally, driven by Zusduri's strong launch as the only approved non-surgical LG-IR-NMIBC therapy. Zusduri's rapid uptake, favorable patient preference,…
defenseworld.net Urogen Pharma (NASDAQ:URGN) Stock Has Consensus Price Target of $52.38 According to Analysts Shares of Urogen Pharma (NASDAQ: URGN - Get Free Report) have been given an average recommendation of "Moderate Buy" by the ten brokerages that are presently covering the stock, Marketbeat reports.…
zacks.com Here's Why You Should Add URGN Stock to Your Portfolio Now UroGen's Zusduri sales surge, Jelmyto revenues and advancing pipeline assets strengthen its shift toward a commercial growth story.
defenseworld.net Critical Analysis: Zoetis (NYSE:ZTS) and Urogen Pharma (NASDAQ:URGN) Zoetis (NYSE: ZTS - Get Free Report) and Urogen Pharma (NASDAQ: URGN - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the…
seekingalpha.com Urogen Pharma: Upside After Bladder Cancer Launch UroGen Pharma Ltd. has transitioned into a commercial-stage biopharma, driven by strong adoption of Zusduri for recurrent non-muscle invasive bladder cancer. Zusduri achieved an 80% complete response…
zacks.com Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus Zacks spotlights Oportun Financial, Uranium Royalty and Amgen, alongside standout gains from its key stock portfolios.
globenewswire.com UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and…
globenewswire.com UroGen Pharma to Present at Upcoming Investor Conferences PRINCETON, N.J., Sept. 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
defenseworld.net BlackRock Inc. Purchases Shares of 3,201,461 Urogen Pharma $URGN BlackRock Inc. purchased a new position in Urogen Pharma (NASDAQ: URGN) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The…
zacks.com Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet The consensus price target hints at a 27.1% upside potential for Urogen Pharma (URGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings…
prnewswire.com IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies IntraGel secures up to $7 million equity investment from UroGen® to advance the Phase 2 clinical study of TumoCure, for the treatment of advanced head and neck cancer UroGen gains access to…
benzinga.com UroGen Pharma Announces Strategic Option And Research License Agreement And Related Equity Investment Agreement With IntraGel Therapeutics Collaboration grants UroGen a research license and exclusive options to license and develop up to three oncology products utilizing IntraGel's proprietary SRGel platformAgreement also includes an…
globenewswire.com UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline Collaboration grants UroGen a research license and exclusive options to license and develop up to three oncology products utilizing IntraGel's proprietary SRGel platform Agreement also includes an…
benzinga.com UroGen Pharma Submits NDA To FDA For Its Investigational Drug UGN-103 For Intravesical Solution UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the submission of a…
globenewswire.com UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC PRINCETON, N.J., Aug. 17, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.- benzinga.com Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $58 Guggenheim analyst Michael Schmitz maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $42 to $58.
benzinga.com HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $75 HC Wainwright & Co. analyst Raghuram Selvaraju maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $45 to $75.- benzinga.com TD Cowen Maintains Buy on UroGen Pharma, Raises Price Target to $60 TD Cowen analyst Tara Bancroft maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $50 to $60.
- benzinga.com UroGen Pharma Q2 EPS $(0.28) Beats $(0.29) Estimate, Sales $72.456M Beat $63.526M Estimate UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.29) by 3.45 percent. This is a 73.33 percent increase over losses of…
- benzinga.com Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $42 Guggenheim analyst Brad Canino maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $32 to $42.
- benzinga.com Oppenheimer Maintains Outperformer on UroGen Pharma, Raises Price Target to $50 Oppenheimer analyst Leland Gershell maintains UroGen Pharma (NASDAQ:URGN) with a Outperformer and raises the price target from $40 to $50.
- benzinga.com UroGen Receives USPTO Notice Of Allowance For Patent Covering Treatment Of Recurrent LG-IR-NMIBC With Thermally Gelling Mitomycin; Claims Supported By ENVISION And ATLAS Trials, Patent To Expire July 2044 UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has received…
- benzinga.com UroGen Pharma Receives FDA IND Application Clearance For Its Investigational Oncolytic Virus UGN-501 The IND clearance enables initiation of a planned Phase 1 clinical study in patients with non-muscle invasive bladder cancer (NMIBC). The Phase 1 study is expected to begin in Q4 2026 and will…
benzinga.com HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $45 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $45 price target.- benzinga.com UroGen Pharma Announces Settlement And License Agreement With Teva Pharmaceuticals Relating to JELMYTO This Agreement resolves the patent litigation UroGen initiated in response to Teva's submission of an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration ("FDA") seeking…
benzinga.com HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $45 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $45 price target.- benzinga.com UroGen Announces That UGN-103 Achieved A 94.5% Durability Of Response At Six Months In The Ongoing Phase 3 UTOPIA Trial For Intravesical Solution In Patients With Bladder Cancer The six-month results from UTOPIA are generally consistent with the 91.9% (95% CI: 86.9, 95.0) six-month DOR observed with ZUSDURI™ (mitomycin) for intravesical therapy in its pivotal ENVISION trial.…
benzinga.com UroGen Pharma Announces 36-Month Duration Of Response By Kaplan-Meier Estimate In Patients Who Achieved Complete Response At Three Months In Pivotal Phase 3 ENVISION Trial Of ZUSDURI For Intravesical Solution. 64.5% Probability of Remaining Event-Free at Three Years by Kaplan-Meier Analysis After Achieving Complete Response at Three MonthsFirst and Only FDA-Approved Medicine for Recurrent Low-Grade…- benzinga.com HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $45 HC Wainwright & Co. analyst Raghuram Selvaraju maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $40 to $45.
- benzinga.com Oppenheimer Maintains Outperform on UroGen Pharma, Raises Price Target to $40 Oppenheimer analyst Leland Gershell maintains UroGen Pharma (NASDAQ:URGN) with a Outperform and raises the price target from $34 to $40.
benzinga.com Earnings Scheduled For May 6, 2026 
benzinga.com UroGen Pharma Reports Q1 2026 Results: Full Earnings Call Transcript - benzinga.com UroGen Pharma Q1 EPS $(0.47) Beats $(0.48) Estimate, Sales $50.959M Beat $44.820M Estimate UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.48) by 2.08 percent. This is a 48.91 percent increase over losses of…
- benzinga.com Earnings Scheduled For March 2, 2026
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com Earnings Scheduled For November 6, 2025